In vitro studies on AMP-001/002/003 demonstrated a) selective cytotoxicity in cancer cells and are shown to be synergistic with doxorubicin while, in vivo models will provide a proof of concept on targeting AMPs to cancer cells and synergy in biological environment with chemotherapy. This evidence concerns the gene ADSL and cancer.